Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2025-09-02 Regulatory Filings
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It provides an update on clinical trial data analysis and references incorporation by reference into other registration statements. The document length is short (2648 characters) and it primarily serves as an announcement of new data rather than a full financial or management report. It does not contain detailed financial statements or comprehensive analysis typical of annual or interim reports. It also does not fit into categories like earnings release, management reports, or capital updates. Given these characteristics, the document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-09-02 English
REPORT OF FOREIGN PRIVATE ISSUER
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, NeuroSense Therapeutics Ltd., with the SEC. It includes exhibits that are a Notice and Proxy Statement for the Annual General Meeting (AGM) and a Proxy Card. The document itself is a report containing these materials, not the AGM presentation or the actual proxy solicitation materials alone. Given the presence of the Notice and Proxy Statement for the AGM, this filing is best classified as Proxy Solicitation & Information Statement (PSI). The document length is short (1819 characters), but it contains the actual proxy statement and notice, not just an announcement of their availability, so it is not a Report Publication Announcement (RPA). Therefore, the classification is PSI with high confidence.
2025-08-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, NeuroSense Therapeutics Ltd., under the Securities Exchange Act of 1934. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The content includes an update on a clinical study and a signature by the CEO, but it does not contain comprehensive financial statements or detailed financial analysis. The document length is short (2133 characters), and it serves as a report of current events or updates rather than a full annual or interim report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2025-08-20 English
Regulatory Filings 2025
Regulatory Filings
2025-08-19 English
Regulatory Filings 2025
Regulatory Filings
2025-08-19 English
REGISTRATION STATEMENT
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes detailed information about the employee share incentive plan, indemnification of directors and officers, and references to other SEC filings. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive regulatory filing.
2025-08-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.